Cargando…
Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents
Human enterovirus (EV) belongs to the picornavirus family, which consists of over 200 medically relevant viruses. A peptidomimetic inhibitor AG7088 was developed to inhibit the 3C protease of rhinovirus (a member of the family), a chymotrypsin-like protease required for viral replication, by forming...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125518/ https://www.ncbi.nlm.nih.gov/pubmed/18583140 http://dx.doi.org/10.1016/j.bmc.2008.06.015 |
_version_ | 1783515962910179328 |
---|---|
author | Kuo, Chih-Jung Shie, Jiun-Jie Fang, Jim-Min Yen, Guei-Rung Hsu, John T.-A. Liu, Hun-Ge Tseng, Sung-Nain Chang, Shih-Cheng Lee, Ching-Yin Shih, Shin-Ru Liang, Po-Huang |
author_facet | Kuo, Chih-Jung Shie, Jiun-Jie Fang, Jim-Min Yen, Guei-Rung Hsu, John T.-A. Liu, Hun-Ge Tseng, Sung-Nain Chang, Shih-Cheng Lee, Ching-Yin Shih, Shin-Ru Liang, Po-Huang |
author_sort | Kuo, Chih-Jung |
collection | PubMed |
description | Human enterovirus (EV) belongs to the picornavirus family, which consists of over 200 medically relevant viruses. A peptidomimetic inhibitor AG7088 was developed to inhibit the 3C protease of rhinovirus (a member of the family), a chymotrypsin-like protease required for viral replication, by forming a covalent bond with the active site Cys residue. In this study, we have prepared the recombinant 3C protease from EV71 (TW/2231/98), a particular strain which causes severe outbreaks in Asia, and developed inhibitors against the protease and the viral replication. For inhibitor design, the P3 group of AG7088, which is not interacting with the rhinovirus protease, was replaced with a series of cinnamoyl derivatives directly linked to P2 group through an amide bond to simplify the synthesis. While the replacement caused decreased potency, the activity can be largely improved by substituting the α,β-unsaturated ester with an aldehyde at the P1′ position. The best inhibitor 10b showed EC(50) of 18 nM without apparent toxicity (CC(50) > 25 μM). Our study provides potent inhibitors of the EV71 3C protease as anti-EV71 agents and facilitates the combinatorial synthesis of derivatives for further improving the inhibitory activity. |
format | Online Article Text |
id | pubmed-7125518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71255182020-04-08 Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents Kuo, Chih-Jung Shie, Jiun-Jie Fang, Jim-Min Yen, Guei-Rung Hsu, John T.-A. Liu, Hun-Ge Tseng, Sung-Nain Chang, Shih-Cheng Lee, Ching-Yin Shih, Shin-Ru Liang, Po-Huang Bioorg Med Chem Article Human enterovirus (EV) belongs to the picornavirus family, which consists of over 200 medically relevant viruses. A peptidomimetic inhibitor AG7088 was developed to inhibit the 3C protease of rhinovirus (a member of the family), a chymotrypsin-like protease required for viral replication, by forming a covalent bond with the active site Cys residue. In this study, we have prepared the recombinant 3C protease from EV71 (TW/2231/98), a particular strain which causes severe outbreaks in Asia, and developed inhibitors against the protease and the viral replication. For inhibitor design, the P3 group of AG7088, which is not interacting with the rhinovirus protease, was replaced with a series of cinnamoyl derivatives directly linked to P2 group through an amide bond to simplify the synthesis. While the replacement caused decreased potency, the activity can be largely improved by substituting the α,β-unsaturated ester with an aldehyde at the P1′ position. The best inhibitor 10b showed EC(50) of 18 nM without apparent toxicity (CC(50) > 25 μM). Our study provides potent inhibitors of the EV71 3C protease as anti-EV71 agents and facilitates the combinatorial synthesis of derivatives for further improving the inhibitory activity. Elsevier Ltd. 2008-08-01 2008-06-13 /pmc/articles/PMC7125518/ /pubmed/18583140 http://dx.doi.org/10.1016/j.bmc.2008.06.015 Text en Copyright © 2008 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Kuo, Chih-Jung Shie, Jiun-Jie Fang, Jim-Min Yen, Guei-Rung Hsu, John T.-A. Liu, Hun-Ge Tseng, Sung-Nain Chang, Shih-Cheng Lee, Ching-Yin Shih, Shin-Ru Liang, Po-Huang Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title_full | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title_fullStr | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title_full_unstemmed | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title_short | Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents |
title_sort | design, synthesis, and evaluation of 3c protease inhibitors as anti-enterovirus 71 agents |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125518/ https://www.ncbi.nlm.nih.gov/pubmed/18583140 http://dx.doi.org/10.1016/j.bmc.2008.06.015 |
work_keys_str_mv | AT kuochihjung designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT shiejiunjie designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT fangjimmin designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT yengueirung designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT hsujohnta designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT liuhunge designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT tsengsungnain designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT changshihcheng designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT leechingyin designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT shihshinru designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents AT liangpohuang designsynthesisandevaluationof3cproteaseinhibitorsasantienterovirus71agents |